HROW
Drug Manufacturers - Specialty & Generic · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Harrow, Inc. publishes a filing, an earnings call transcript or a press release.
Get HROW alertsThe proxy statement of Harrow, Inc. reports total compensation of $1,342,627 for Amir Shojaei in fiscal 2025, including a base salary of $441,346. Amir Shojaei has spoken on 3 earnings calls across 1 company, most recently for Harrow, Inc. on November 10, 2026. Harrow, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Harrow, Inc. includes Francis W. Mullery (CEO), Frank Mullery (CEO), John P. Saharek (CEO) and 7 others.
“Then the only thing I'll add is currently we don't have any plans for a second study or further studies in this line. That said, we do have quite a few ongoing studies with investigator-initiated trials within the IHESO franchise.”
“As I mentioned during our last quarterly webcast, we have now officially secured our pre-MDA meeting with the FDA, which is scheduled for early in the fourth quarter.”
“I wanted to spend a few minutes on G-Melt, our IV and opioid-free procedural sedation candidate. Having spent nearly 30 years in drug development advancing major global assets, I view G-MELT as a pipeline candidate of the highest caliber.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
HROW
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Harrow, Inc. (HROW) | Chief Scientific Officer | $441,346 | $1,342,627 |